TheEdgeResearch
Home / Stocks / VX1.DE

Vertex Pharmaceuticals Incorporated (VX1.DE)

XETRA Healthcare Biotechnology
$458.85 ▼ -0.21%
Market Cap
$116.46B
Sector
Healthcare
Industry
Biotechnology
Beta
0.14
52-Wk Range
320.75-464
CEO
Reshma Kewalramani
Country
US
Currency
EUR

Vertex Pharmaceuticals Incorporated operates in the Biotechnology industry of the Healthcare sector, headquartered in Boston, MA, US. The stock last traded at $458.85, down 0.21% on the session, giving a market capitalisation of $116.46B. Its beta of 0.14 implies it has historically moved less than the broad market.

Company profile
Exchange
Deutsche Börse
Employees
6,400
IPO date
2007-12-28
Headquarters
Boston, MA, US
About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily engaged in the development and commercialization of groundbreaking treatments for cystic fibrosis. Its existing portfolio includes therapies such as SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, prescribed for individuals with cystic fibrosis who exhibit particular mutations in their cystic fibrosis transmembrane conductance regulator gene. Additionally, TRIKAFTA is available for CF patients aged six and older possessing at least one F508del mutation. Beyond CF, Vertex maintains a robust development pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin deficiency; VX-147, also in Phase 2, targeting APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other significant renal conditions; VX-880, a Type 1 Diabetes treatment undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor for acute, neuropathic, and musculoskeletal pain, in Phase 2; and CTX001, a Phase 3 candidate for severe sickle cell disease (SCD) and transfusion-dependent thalassemia (TDT). The company distributes its products through specialty pharmacies and distributors within the United States, and globally via specialty distributors, retail chains, hospitals, and clinics. Vertex actively collaborates with numerous entities including Affinia Therapeutics, Inc., Arbor Biotechnologies, Inc., CRISPR Therapeutics AG., Kymera Therapeutics, Inc., Mammoth Biosciences, Inc., Moderna, Inc., Obsidian Therapeutics, Inc., Skyhawk Therapeutics, Inc., Ribometrix, Inc., Genomics plc, Merck KGaA, Darmstadt, Germany, and X-Chem, Inc. Founded in 1989, Vertex Pharmaceuticals Incorporated is headquartered in Boston, Massachusetts.

Comparable companies

Vertex Pharmaceuticals Incorporated is most often compared with the following Healthcare names:

BRM.DECVS.DEDUL.DEGIS.DEPFE.DEPFE.FSNW.DESYK.DEZOE.DE
More research on VX1.DE
VX1.DE technical analysis VX1.DE TheEdge Score Compare against peers
Open full interactive analysis & DCF →